Aarti Pharmalabs Ltd (AARTIPHARM) Q4FY25 Concall Summary - Mar-2025 Qtr
Performance Overview
- Aarti Pharmalabs Ltd reported record EBITDA and PAT for FY25, driven by strong performance across all segments (Xanthine derivatives, API intermediates, and CDMO/CMO).
- Q4 FY25 revenue reached Rs. 564 crores, an 11% YoY increase, while full-year revenue was Rs. 2,113 crores, up 14% YoY.
- EBITDA for Q4 FY25 was Rs. 146 crores, a 24% YoY increase, with margins expanding to 26%. Full-year EBITDA grew by 20% YoY to Rs. 464 crores.
- Q4 FY25 PAT surged by 35% YoY to Rs. 88 crores. FY25 PAT reached Rs. 272 crores, a 26% increase over FY24.
- The company achieved a strong net cash flow from operations of Rs. 332 crores in FY25.
Financial Metrics
Log in to Stocksigma to read the Financial Metrics section of this summary.
Operating Performance / Business Segments
Log in to Stocksigma to read the Operating Performance / Business Segments section of this summary.
Key Discussions & Insights
Log in to Stocksigma to read the Key Discussions & Insights section of this summary.
Outlook and Guidance
Log in to Stocksigma to read the Outlook and Guidance section of this summary.
Challenges / Concerns
Log in to Stocksigma to read the Challenges / Concerns section of this summary.
Industry / Competitive Landscape
Log in to Stocksigma to read the Industry / Competitive Landscape section of this summary.
Overall Summary
Log in to Stocksigma to read the Overall Summary section of this summary.